The authors hypothesized a predicting role for the peroxisome proliferator-activated receptor (PPAR), a transcription factor which is involved in tumor growth and whose activation leads to SCD5 gene expression, in affecting the response to taxane-based chemotherapy in breast cancer. The gene discussed is SCD5; the disease is breast carcinoma.